Artificial intelligence in medicine regulation: from concept to practice

The European Medicines Agency (EMA) and the European medicines regulatory network are using artificial intelligence (AI) in medicine regulation to achieve concrete outcomes, such as helping develop higher-quality medicines more quickly.
HumanVeterinaryAIData on medicines

Portuguese is available via eTranslation, the European Commission's machine translation service.

Translate to Portuguese | Important information about machine translation

Artificial intelligence (AI) refers to computer systems that use data to analyse information and generate outputs such as predictions, recommendations, content or decisions. These outputs can help people perform tasks, gain insights from data and support decision-making. Certain AI systems can adapt and improve their performance based on experience.

This concept of AI is in line with Regulation (EU) 2024/1689 - also known as the AI Act. 

EMA and the European medicines regulatory network are transitioning from concept to practice in the use of AI in medicine regulation. This transition mirrors developments in the pharmaceutical industry, which makes use of AI at every step in the medicine lifecycle: from drug discovery, through development and manufacturing, to safety monitoring.

For more information about EMA's work on AI, see:

Desired outcomes of AI use in medicine regulation

Using AI in medicine regulation is leading to advances in fields such as:

  • Data analytics
  • Automation
  • Machine learning
  • Digital twins

These advance are creating new opportunities to enhance key areas like:

  • Product quality
  • Manufacturing efficiency
  • Supply chain resilience
  • Decision-making in medicine regulation

EMA expects the AI transition in medicine regulation to help achieve concrete, positive outcomes including:

  • Speeding up development of medicines
  • Optimising clinical evidence and medicine quality – clarifying key aspects such as whether and in what populations a medicine works and is safe
  • Delivering high-quality regulatory work – through outcomes such as faster assessment of product applications, more precise advice for the pharmaceutical industry and an expert workforce able to reap the benefits of AI

For more information on the desired outcomes of using AI in medicine regulation, see: 

AI at EMA: timeline

A timeline of AI-related milestones and events at EMA is available below. 

This is not a complete list. For more details, see content highlighted under the 'In this section', 'Scientific publications', 'Events' and 'News' sections on this page.

  1. Regulatory research priorities for AI use in the medicine lifecycle

    Scientific article co-signed by EMA staff published in the 'Clinical Pharmacology & Therapeutics' journal

    August 2026

  2. EMA AI Observatory report for 2025

    Report published on EMA corporate website

    June 2026

  3. Microsoft Copilot 365 rolled out at EMA

    Copilot 365 made available to all EMA staff subject to licensing training, managerial approval and monitoring of use

    June 2026

  4. Enhanced functionality for EMA's AI-enabled knowledge mining tool 'Scientific Explorer'

    FAQ document on Scientific Explorer updated on EMA corporate website

    March 2026

  5. NDSG workplan 2026-2028: Data and artificial intelligence in medicines regulation

    Workplan published on EMA corporate website

    March 2026

  6. Common EMA-FDA principles for AI in medicine development

    Document published on EMA corporate website

    November 2025

  7. EMA AI Observatory report for 2024

    Report published on EMA corporate website

    July 2025

  8. European medicines agencies network strategy to 2028

    Strategy focusing on leveraging data, digitalisation and artificial intelligence published on EMA corporate website, following public consultation between October and November 2024

    March 2025

  9. First EMA qualification opinion on AI methodology

    EMA's CHMP issued a qualification opinion on this AI-based innovative development methodology

    March 2025

  10. Guiding principles on the use of LLMs in regulatory science and medicines regulation

    Guidance published on EMA corporate website

    September 2024

  11. Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle

    Reflection paper published on EMA corporate website, following public consultation between July and December 2023

    September 2024

  12. AI-enabled knowledge mining tool 'Scientific Explorer'

    Scientific Explorer first launched, FAQ document published on EMA corporate website

    March 2024

  13. EMA-HMA Big Data Stakeholder Forum

    'Regulatory preparedness on Artificial Intelligence: AI workplan' among the key presentations at this forum

    December 2023

  14. Joint EMA-HMA AI workshop: Smart regulation in a rapidly evolving world

    Full-day workshop with agenda and video recordings available on EMA corporate website

    November 2023

  15. EMA-HMA Big Data Stakeholder Forum

    'AI in medicines regulation' among the key presentations at this forum

    December 2022

  16. Joint EMA-HMA workshop on artificial intelligence in medicines regulation

    Full-day workshop with presentations, agenda, video recordings and report available on EMA corporate website

    April 2021

Page update history

An update log is available to show the date and summary of changes to this webpage. It does not include updates to linked documents or minor edits like typos or broken link fixes.

The tracking of updates begins in November 2026.

11 November 2026

Page first published

Share this page